⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13625787 | 0.83 | CYP2E1 (0.47) | — | |
| SCHEMBL26076115 | 0.82 | — | — | |
| SCHEMBL29807285 | 0.82 | — | — | |
| SCHEMBL7663988 | 0.82 | — | — | |
| SCHEMBL4852032 | 0.81 | RAB9A (0.40) | — | |
| SCHEMBL25774612 | 0.79 | TYR (0.52) | — | |
| SCHEMBL4852017 | 0.79 | RAB9A (0.39) | — | |
| SCHEMBL3027128 | 0.79 | — | — | |
| SCHEMBL877689 | 0.78 | CYP2E1 (0.48) | — | |
| SCHEMBL29418900 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4293024-B1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706774-A2 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | ASTELLAS PHARMA INC. (JP) | 2025-08-12 | — | — | US | disclosed |
| US-20250064946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2025-02-27 | — | — | US | disclosed |
| CN-118317774-A | Pharmaceutical compositions comprising quinazoline compounds | 安斯泰来制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| US-20240182483-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2024-06-06 | — | — | US | disclosed |
| EP-4293024-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D-MUTATION KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2023-12-20 | — | — | EP | disclosed |
| CN-116848120-A | Quinazoline compounds for inducing G12D mutant KRAS proteolysis | 安斯泰来制药株式会社 | 2023-10-03 | — | — | CN | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023119677-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023120742-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2023-06-29 | — | — | WO | disclosed |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| WO-2009140448-A1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |